Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
271
Recruiting, any sponsor type, condition "myelodysplastic"
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting271
- Completed1,182
271 trials
Showing 1 to 25, recently updated first.
Abhay Singh, MD MPHAcademic, hospital or other
NCT06630221 · 25 participants (planned) · Start Jun 17, 2025 · Primary completion Jan 1, 2028
Drug: Eltrombopag (EPAG) · For: Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia
Sites: Cleveland, Ohio
National Cancer Institute (NCI)NIH
NCT06303193 · 160 participants (planned) · Start Nov 25, 2026 · Primary completion Jan 1, 2030
Drug: pacritinib · For: Myelodysplastic Syndromes
Sites: Bethesda, Maryland
- Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia PatientsRecruiting
Haikou Affiliated Hospital of Central South University Xiangya School of MedicineAcademic, hospital or other
NCT07763054 · 30 participants (planned) · Start Aug 1, 2025 · Primary completion Aug 31, 2026
Drug: Liposomal Amphotericin B · For: Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Myelodysplastic Syndrome and 6 more
Sites: Hainan, China
Orca Biosystems, Inc.Industry
NCT07216443 · 130 participants (planned) · Start Dec 9, 2025 · Primary completion Nov 2028
Drug: Orca-T · For: Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Mixed Phenotype Acute Leukemia
Sites: Duarte, California; Los Angeles, California; Denver, Colorado · 9 sites in all
Fred Hutchinson Cancer CenterAcademic, hospital or other
NCT04195633 · 60 participants (planned) · Start Jan 25, 2021 · Primary completion Apr 15, 2027
Drug: Cyclophosphamide; Cyclosporine and 5 more · For: Acute Leukemia; Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia and 16 more
Sites: Seattle, Washington
Immune System Key LtdIndustry
NCT04365179 · 18 participants (planned) · Start Jun 18, 2020 · Primary completion Dec 31, 2027
Drug: Nerofe · For: Advanced MDS; AML
Sites: Miami, Florida
Fred Hutchinson Cancer CenterAcademic, hospital or other
NCT06928662 · 36 participants (planned) · Start Sep 23, 2025 · Primary completion Mar 9, 2028
Drug: Decitabine; Cytarabine and 3 more · For: Acute Myeloid Leukemia; Acute Undifferentiated Leukemia; Mixed Phenotype Acute Leukemia and 11 more
Sites: Seattle, Washington
- A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)Pivotal-lookingRecruiting
Swedish Orphan BiovitrumIndustry
NCT06782373 · 156 participants (planned) · Start May 28, 2025 · Primary completion Oct 30, 2028
Drug: Pacritinib; Placebo · For: VEXAS; VEXAS Syndrome
Sites: Scottsdale, Arizona; Boston, Massachusetts; Rochester, Minnesota · 39 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07753148 · 52 participants (planned) · Start Sep 17, 2026 · Primary completion May 5, 2031
Drug: REGN17235 · For: Clonal Cytopenia of Undetermined Significance (CCUS); Low-Risk Myelodysplastic Syndrome (LR-MDS)
Sites: Ghent, Belgium; Roeselare, Belgium; London, United Kingdom
National Cancer Institute (NCI)NIH
NCT06577441 · 54 participants (planned) · Start Jun 12, 2025 · Primary completion Mar 1, 2027
Drug: Decitabine and Cedazuridine; Enasidenib · For: Myelodysplastic Syndrome
Sites: Berkeley, California; Irvine, California; Orange, California · 152 sites in all
National Cancer Institute (NCI)NIH
NCT06661915 · 78 participants (planned) · Start Aug 14, 2025 · Primary completion Dec 31, 2027
Drug: Decitabine and Cedazuridine; Iadademstat · For: Accelerated Phase Myeloproliferative Neoplasm; Blast Phase Myeloproliferative Neoplasm; Essential Thrombocythemia and 5 more
Sites: Irvine, California; Orange, California; Palo Alto, California · 32 sites in all
Faron Pharmaceuticals LtdIndustry
NCT07672769 · 90 participants (planned) · Start Nov 2026 · Primary completion Nov 2027
Drug: bexmarilimab (1mg/kg); azacitidine and 2 more · For: Higher Risk Myelodysplastic Syndromes
Sites: Duarte, California; Aurora, Colorado; New Haven, Connecticut · 35 sites in all
Marker Therapeutics, Inc.Industry
NCT06552416 · 40 participants (planned) · Start Jun 16, 2025 · Primary completion Sep 2029
Drug: MT-401-OTS · For: Acute Myeloid Leukemia, in Relapse; MDS
Sites: Duarte, California; Tampa, Florida; Kansas City, Kansas
University of Wisconsin, MadisonAcademic, hospital or other
NCT07758218 · 22 participants (planned) · Start Nov 2026 · Primary completion Oct 2029
Drug: agenT-797 · For: Allogenic Stem Cell Transplantation; Myeloid Malignancies; Lymphoid Malignancies and 3 more
Sites: Madison, Wisconsin
- Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2Pivotal-lookingRecruiting
University of UlmAcademic, hospital or other
NCT04628026 · 650 participants (planned) · Start Sep 13, 2022 · Primary completion Mar 2029
Drug: Venetoclax; Placebo · For: Acute Myeloid Leukemia
Sites: Innsbruck, Austria; Linz, Austria; Rankweil, Austria · 91 sites in all
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT02115295 · 508 participants (planned) · Start May 19, 2014 · Primary completion May 31, 2030
Drug: Cladribine; Cytarabine and 4 more · For: Acute Biphenotypic Leukemia; Acute Myeloid Leukemia; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and 11 more
Sites: Houston, Texas
University Hospital TuebingenAcademic, hospital or other
NCT07214064 · 27 participants (planned) · Start Feb 19, 2026 · Primary completion Aug 2027
Drug: RIC regimen · For: AML (Acute Myeloid Leukemia); MDS/AML; MDS (Myelodysplastic Syndrome)
Sites: Tübingen, Germany
- ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDSRecruiting
Washington University School of MedicineAcademic, hospital or other
NCT07617363 · 36 participants (planned) · Start Nov 30, 2026 · Primary completion Oct 31, 2029
Drug: ATRN-119; Decitabine · For: Acute Myeloid Leukemia; High-risk Myelodysplastic Syndrome
Sites: St Louis, Missouri
University of Michigan Rogel Cancer CenterAcademic, hospital or other
NCT07737769 · 20 participants (planned) · Start Oct 26, 2026 · Primary completion Nov 2028
Drug: Arsenic Trioxide; Busulfan and 1 more · For: Acute Myeloid Leukemia; Myelodysplastic Syndrome
Sites: Ann Arbor, Michigan
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT03589729 · 100 participants (planned) · Start Sep 19, 2018 · Primary completion Dec 31, 2027
Drug: Cladribine; Cytarabine and 3 more · For: Acute Myeloid Leukemia; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Blasts 10 Percent or More of Bone Marrow Nucleated Cells and 4 more
Sites: Houston, Texas
City of Hope Medical CenterAcademic, hospital or other
NCT06996119 · 15 participants (planned) · Start Jun 12, 2026 · Primary completion Nov 5, 2028
Drug: Busulfan; Cyclophosphamide and 5 more · For: Acute Myeloid Leukemia; Graft Versus Host Disease; Myelodysplastic Syndrome
Sites: Duarte, California
- Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)Pivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT05554406 · 335 participants (planned) · Start Sep 25, 2024 · Primary completion Mar 31, 2027
Drug: Azacitidine; Cytarabine and 3 more · For: Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm; Acute Myeloid Leukemia Post Cytotoxic Therapy and 1 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 227 sites in all
Uma BorateAcademic, hospital or other
NCT06523556 · 49 participants (planned) · Start Aug 2, 2024 · Primary completion Oct 31, 2027
Drug: Axatilimab; Azacitidine · For: Atypical Chronic Myeloid Leukemia; Chronic Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm and 5 more
Sites: Columbus, Ohio; Portland, Oregon
Rigel PharmaceuticalsIndustry
NCT05308264 · 86 participants (planned) · Start Sep 12, 2022 · Primary completion Dec 2027
Drug: R906289 Monosodium (R289 Na) · For: Low Risk Myelodysplastic Syndromes
Sites: Los Angeles, California; Orange, California; Palo Alto, California · 13 sites in all
- A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood TransfusionsPivotal-lookingRecruiting
TakedaTakeda (TAK)
NCT07422480 · 300 participants (planned) · Start May 21, 2026 · Primary completion Apr 30, 2029
Drug: Elritercept; Epoetin Alfa · For: Myelodysplastic Syndrome; Anemia
Sites: Gilbert, Arizona; Duarte, California; Santa Rosa, California · 166 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.